Antifungal therapy

Clinical Mycology

Volumn , Issue , 2009, Pages 161-195

  Gubbins, Paul O ^a   Anaissie, Elias J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865579381     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5680-5.00007-4     Document Type: Chapter

References (254)

1. Espinel-Ingroff A. History of medical mycology in the United States. Clin Microbiol Rev 1996, 9:235.
2. Gilchrist T.C. Protozoan dermatitidis. J Cutaneous Dis 1894, 12:496.
3. Mercurio M.G., Elewski B.E. Therapy of sporotrichosis. Semin Dermatol 1993, 12:285.
4. Sheehan D.J., Hitchcock C.A., Sibley C.M. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999, 12:40.
5. Oxford A.E., Raistrick H., Simonart P. Studies on the biochemistry of microorganisms 60. Griseofulvin, C17H17O6Cl, a metabolic product of Penicillium griseofulvum Dierckx. Biochem J 1939, 33:240.
6. Wooley D.W. Some biological effects produced by benzimidazole and their reversal by purines. J Biol Chem 1944, 152:225.
7. Elson W.O. The antibacterial and fungistatic properties of propamidine. J Infect Dis 1945, 76:193.
8. Hazen E.L., Brown R. Two antifungal agents produced by a soil actinomycete. Science 1950, 112:423.
9. Hazen E.L., Brown R. Fungicidin, antibiotic produced by soil actinomycete. Proc Soc Exp Biol Med 1951, 76:93.
10. Schoenbach E.B., Miller J.M., Ginsberg M., Long P.H. Systemic blastomycosis treated with stilbamidine. JAMA 1951, 146:1317.
11. Snapper I., McVay L.V. The treatment of North American blastomycosis with 2-hydroxystilbamidine. Am J Med 1953, 15:603.
12. Gold WH, Stout A, Pagano JF, Donovick R. Amphotericin A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies of A. Antibiot Annu 3:579-586, 1955-1956.
13. Harrell E.R., Curtis A.C. The treatment of North American blastomycosis with amphotericin B. Arch Dermatol 1957, 76:561.
14. Sawyer P.R., Brogden R.N., Pinder R.M., et al. Clotrimazole. Drugs 1975, 9:424.
15. Heel R.C., Brogden R.N., Pakes G.E., et al. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs 1980, 19:7.
16. Burgess M.A., Bodey G.P. Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies. Antimicrob Agents Chemother 1972, 2:423.
17. Fainstein V., Bodey G.P. Cardiorespiratory toxicity due to miconazole. Ann Intern Med 1980, 93:432.
18. Espinel-Ingroff A., Shadomy S., Gebhart R.J. In vitro studies with R 51211 (itraconazole). Antimicrob Agents Chemother 1984, 26:5.
19. Ghannoum M.A., Rice L.B. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999, 12:501.
20. Georgopapadakou N.H., Walsh T.J. Human mycoses: drugs and targets for emerging pathogens. Science 1994, 264:371.
21. Brajtburg J., Powderly W.G., Kobayashi G.S., Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother 1990, 34:183.
22. vanden Bossche H., Marichal P., Gorrens J., et al. Mode of action studies: basis for the search of new antifungal drugs. Ann NY Acad Sci 1988, 544.
23. Sanati H., Belanger P., Rutilio F., Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997, 41:2492.
24. Ryder N.S. Squalene epoxidase as a target for the allylamines. Biochem Soc Trans 1991, 19:774.
25. Ryder N.S. Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent. Antimicrob Agents Chemother 1985, 27:252.
26. Ryder N.S., Dupont M.C. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of the fungal and mammalian enzymes. Biochem J 1985, 130:765.
27. Ryder N.S., Frank I., Dupont M.C. Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclate. Antimicrob Agents Chemother 1986, 29:858.
28. Mercer E.I. Morpholine antifungals and their mode of action. Biochem Soc Trans 1991, 19:788.
29. Haria M., Bryson H.M. Amorolfine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 1995, 49:103.
30. Atkinson G.W., Israel H.L. 5-fluorocytosine treatment of meningeal and pulmonary aspergillosis. Am J Med 1973, 55:496.
31. Hector R.F. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993, 6:1.
32. Carillo-Munoz A.J., Giusiano G., Ezkurra P.A. Antifungal agents: mode of action in yeast cells. Rev Esp Quimoterap 2006, 19:130.
33. Igarashi Y., Futamata K., Fujita T., et al. A novel antifungal antibiotic produced by Streptomyces sp. TP-A0356. J Antibiot (Tokyo) 2003, 56:107.
34. Petraitiene R., Petraitis V., Kelaher A.M., et al. Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2005, 49:2084.
35. Gonzalbo D., Elorza M.V., Sanjuan R., et al. Critical steps in fungal cell wall synthesis: strategies for their inhibition. Pharmacol Ther 1993, 60:337.
36. Bulawa C.E. Genetics and molecular biology of chitin synthesis in fungi. Annu Rev Microbiol 1993, 47:505.
37. Debono M., Gordee R.S. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994, 48:471.
38. Dominguez J.M., Kelly V.A., Kinsman O.S. Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob Agents Chemother 1998, 42:2274.
39. Lodge J.K., Jackson-Machelski E., Toffaletti D.L., et al. Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. Proc Natl Acad Sci USA 1994, 91:12008.
40. Georgopapadkou N.H. New cell wall targets for antifungal drugs. Expert Opin Investig Drugs 2001, 10:269.
41. Gallis H.A., Drew R.H., Pickard W.W., Amphotericin B. 30 years of clinical experience. Rev Infect Dis 1990, 12:308.
42. Hervé M., Dubouzy J.C., Borowski E., et al. The role of the carboxyl and amino groups of polyene macrolides in their interactions with sterols and their selective toxicity. A 31 P-NMR study. Biochim Biophys Acta 1989, 980:261.
43. Brajtburg J., Powderly W.G., Kobayashi G.S., Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agent Chemother 1990, 34:183.
44. Norman A.W., Spielvogel A.M., Wong R.G. Polyene antibiotic sterol interaction. J Infect Dis 1984, 149:986.
45. Gruda I., Nadeau J., Brajtburg J., Medoff G. Application of different spectra in the UV-visible region to study the formation of amphotericin B complexes. Biochim Biophys Acta 1980, 602:260.
46. Vertut-Croquin A., Bolard J., Chabert M., Gary-Bobo C. Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol- or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study. Biochemistry 1983, 22:2939.
47. Schell R.E. Proton permeability of renal membranes: influence of amphotericin B. Nephron 1993, 63:481.
48. Hsu S.-F., Burnette R.R. The effect of amphotericin B on the K-channel activity of MDCK cells. Biochim Biophys Acta Protein Struct Mol Enzymol 1993, 1152:189.
49. Velez J.D., Allendoerfer R., Luther M., et al. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis 1993, 168:508.
50. Graybill J.R. The future of antifungal therapy. Clin Infect Dis 1996, 22(suppl 2):S166.
51. Graybill J.R., Sharkey P.K. Fungal infections and their management. Br J Clin Pract 1990, 44(suppl 71):32.
52. Graybill J.R. The modern revolution in antifungal chemotherapy. Mycoses in AIDS 1990, 265. Plenum Press, New York.
53. Cleary J.D., Chapman S.W., Nolan R.L. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob Agents Chemother 1992, 36(5):977.
54. Cha J.K.S., Pollack M. Amphotericin B induces tumor necrosis factor production by murine macrophages. J Infect Dis 1989, 159:113.
55. Wilson E., Thorson L., Speert D.P. Enhancement of macrophage superoxide anion production by amphotericin B. Antimicrob Agents Chemother 1991, 35:796.
56. Spellberg B.J., Filler S.G., Edwards J.E. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006, 42:244.
57. Pfaller M.A., Diekema D.J. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004, 42:4419.
58. Dick J.D., Rosengard R.P., Merz W.G., et al. Fatal disseminated candidiasis due to amphotericin B resistant Candida guilliermondii. Ann Intern Med 1985, 102:67.
59. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133.
60. Pfaller M.A., Boyken L., Messer S.A., et al. Evaluation of the Etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. J Clin Microbiol 2004, 42:4977.
61. Pfaller M.A., Messer S.A., Boyken L., et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004, 42:3142.
62. Yang Y.L., Li S.Y., Chang H.H., Lo H.J. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. Diagn Microbiol Infect Dis 2005, 51:179.
63. Canton E., Peman J., Gobernado M., et al. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother 2004, 48:2477.
64. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N. for the SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002, 46:1032.
65. Sabatelli F., Patel R., Mann P.A., et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006, 50:2009.
66. Sutton D.A., Sanche S.E., Revankar S.G., et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999, 37:2343.
67. Kontoyiannis D.P., Lewis R.E., May G.S., et al. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses 2002, 45:406.
68. Perparim K., Nagai H., Hashimoto A., et al. In vitro susceptibility of Trichosporon beigelii to antifungal agents. J Chemother 1996, 8:445.
69. Bekersky I., Fielding R.H., Dressler D.E., et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002, 46:834.
70. Bekersky I., Fielding R.H., Dressler D.E., et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002, 46:828.
71. Karlowsky J.A., Zhanel G.G. Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin Infect Dis.15 1992, 654.
72. Janknegt R., de Marie S., Bakker-Woudenberg I., Crommelin D.J.A. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 1992, 23:279.
73. Kan V.L., Bennett J.E., Amantea M.A., et al. Comparative safety, tolerance and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers. J Infect Dis 1991, 164:418.
74. Adler-Moore J., Proffitt R.T. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993, 3:429.
75. Andes D., Safdar N., Marchillo K., Conklin R. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006, 50:674.
76. Vogelsinger H., Weiler S., Djanani A., et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother 2006, 57:1153.
77. Hiemenz J.W., Walsh T.J. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996, 22(suppl 2):S133.
78. Groll A.H., Giri N., Petraitis V., et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000, 182:274.
79. Groll A.H., Mickiene D., Piscitelli S.C., Walsh T.J. Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits. Antimicrob Agents Chemother 2000, 44:408.
80. Wasan K.M., Grossie V.B., Lopez-Berestein G. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother 1994, 38:2224.
81. Bratjburg J., Elberg S., Kobayashi G.S., Medoff G. Effects of serum lipoproteins on damage to erythrocytes and Candida albicans cells by polyene antibiotics. J Infect Dis 1986, 153:623.
82. Brajtburg J., Elberg S., Bolard J., et al. Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis 1984, 149:986.
83. Siegel E.B. Measurement of polyene antibiotic-mediated erythrocyte damage by release of hemoglobin and radioactive chromium. Antimicrob Agents Chemother 1977, 11:675.
84. Goodwin S.D., Cleary J.D., Walawander C.A., et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995, 20:755.
85. Gubbins P.O., Penzak S.R., Polston S., et al. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002, 22:961.
86. Heidemann H.T., Gerkens J.F., Spickard W.A., et al. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983, 75:476.
87. MacGregor R.R., Bennett J.E., Ersley A.J. Erythropoietin concentration in amphotericin B induced anemia. Antimicrob Agents Chemother 1978, 14:270.
88. Luber A.D., Maa L., Lam M., Guglielmo B.J. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999, 43:267.
89. de Marie S., Janknegt R., Bakker-Woudenberg I.A.J.M. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994, 33:907.
90. Wong-Beringer A., Jacobs R.A., Guglielmo B.J. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 1998, 27:603.
91. Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 1999, 19:306.
92. Barrett J.P., Vardulaki K.A., Conlon C., et al. A systematic review of antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003, 25:1295.
93. Wingard J.R., White M.H., Anaissie E., et al. L-Amph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid B complex in the empirical treatment of febrile neutropenia. L-Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000, 31:1155.
94. White M.H., Bowden R.A., Sandler E.S., et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998, 27:296.
95. Ostrosky-Zeichner L., Marr K.A., Rex J.H., Cohen S.H., Amphotericin B. time for a new "gold standard.". Clin Infect Dis 2003, 37:415.
96. Polak A., Grenson M. Evidence for a common transport system for cytosine, adenine and hypoxanthine in Saccharomyces cerevisiae and Candida albicans. Eur J Biochem 1973, 32:276.
97. Polak A., Scholer H.J. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy 1975, 21:113.
98. Waldorf A.R., Polak A. Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother 1983, 23:79.
99. Diasio R.B., Bennett J.E., Myers C.E. Mode of action of 5-fluorocytosine. Biochem Pharmacol 1978, 27:703.
100. Polak A.M., Scholer H.J., Wall M. Combination therapy of experimental candidiasis, cryptococcosis, and aspergillosis in mice. Chemotherapy 1982, 28:461.
101. Rex J.H., Walsh T.J., Sobel J.D., et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000, 30:662.
102. Saag M.S., Graybill R.J., Larsen R.A., et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000, 30:710.
103. Cutler R.E., Blair A.D., Kelly M.R. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 1978, 24:333.
104. Daneshmend T.K., Warnock D.W. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983, 8:17.
105. Muther R.S., Bennett W.M. Peritoneal clearance of amphotericin B and 5-flucytosine. West J Med 1980, 133:157.
106. Schönebeck J., Polak A., Fernex M., Scholer H.J. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy 1973, 18:321.
107. Vermes A., van der Sijs I.H., Guchelaar H.J. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy 2000, 46:86.
108. Block E.R., Bennett J.E., Livoti L.G., et al. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance. Studies in man. Ann Intern Med 1974, 80:613.
109. Vermes A., Mathôt R.A.A., van der Sijs I.H., et al. Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM. Ther Drug Monit 2000, 22:676.
110. Perfect J.R., Lindsay M.H., Drew R.H. Adverse drug reactions to systemic antifungals. Prevention and management. Drug Safety 1992, 7:323.
111. Lewis R.E., Klepser M.E., Pfaller M.A. In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. Diagn Microbiol Infect Dis 2000, 36:101.
112. Diaso R.B., Lakings D.E., Bennett J.E. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrob Agents Chemother 1978, 14:903.
113. Harris B.E., Manning B.W., Federle T.W., Diasio R.B. Conversion of 5-fluorocytosine to 5-fluorouracil by intestinal microflora. Antimicrob Agents Chemother 1986, 29:44.
114. Stamm A.M., Diasio R.B., Dismukes W.E., et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987, 83:236.
115. Benson J.M., Nahata M.C. Clinical use of systemic antifungal agents. Clin Pharm 1988, 7:424.
116. Vermes A., Guchelaar H.J., Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000, 46:171.
117. Wheat J., Marichal P., Vanden Bossche H., et al. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob Agent Chemother 1997, 41:410.
118. Groll A.H., Piscitelli S.C., Walsh T.J. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy 2001, 21:133S.
119. Pfaller M.A., Diekema D.J., Gibbs D.L., et al. Global Antifungal Surveillance Study. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007, 45:1735.
120. Pfaller M.A., Messer S.A., Boyken L., et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005, 43:2163.
121. Ramani R., Chaturvedi V. Antifungal susceptibility profiles of Coccidioides immitis and Coccidioides posadasii from endemic and non-endemic areas. Mycopathologia 2007, 163:315.
122. Supparatpinyo K., Chiewchanvit S., Hirunsri P., et al. Penicillium marneffei infection in patients infected with human immunodeficiency virus. Clin Infect Dis 1992, 14:871.
123. Norris S., Wheat J., McKinsey D., et al. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am J Med 1994, 96:504.
124. Diaz M., Negroni R., Montero-Gei F., et al. A pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Clin Infect Dis 1992, 14(suppl 1):S68.
125. Pappas P.G., Bradsher R.W., Chapman S.W., et al. Treatment of blastomycosis with fluconazole: a pilot study. Clin Infect Dis 1995, 20:267.
126. Supparatpinyo K., Khamwan C., Baosoung V., et al. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994, 344:110.
127. Deng Z., Ribas J., Gibson D.W., Connor D.H. Infections caused by Penicillium marneffei in China and southeast Asia. Review of 18 published cases and report of four more cases. Rev Infect Dis 1988, 10:640.
128. Supparatpinyo K., Nelson K.E., Merz W.G., et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993, 37:2407.
129. Pfaller M.A., Boyken L., Hollis R.J., et al. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol 2005, 43:3807.
130. Gonzalez G.M., Fothergill A.W., Sutton D.A., Rinaldi M.G., Loebenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol 2005, 43:281.
131. Almyroudis N.G., Sutton D.A., Fothergill A.W., et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007, 51:2587.
132. Hostetler J.S., Heykants J., Clemons K.V., et al. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob Agents Chemother 1993, 37:2224.
133. Messer S.A., Jones R.N., Fritsche T.R. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 2006, 44:1782.
134. Soczo G., Kardos G., McNicholas P.M., et al. Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species. J Antimicrob Chemother 2007, 60:1004.
135. Espinel-Ingroff A. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother 2001, 45:605.
136. Perfect J.R., Cox G.M., Dodge R.K., Schell W.A. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996, 40:1910.
137. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N. In vitro activities of posaconazole (SCH 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001, 45:2862.
138. Debruyne D., Ryckelynk J.P. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993, 24:10.
139. Pelz R.K., Lipsett P.A., Swoboda M.S., et al. Enteral fluconazole is well absorbed in critically ill surgical patients. Surgery 2002, 131:534.
140. Summers K.K., Hardin T.C., Gore S.J., Graybill J.R. Therapeutic drug monitoring of systemic antifungal therapy. J Antimicrob Chemother 1997, 40:753.
141. 14C] fluconazole in humans. Drug Metab Disp 1991, 19:764.
142. Black D.J., Kunze K.L., Wienkers L.C., et al. Warfarin-fluconazole II A metabolically based drug interaction: in vivo studies. Drug Metab Disp 1996, 24:422.
143. Heykants J., Van Peer A., Van de Velde V., et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989, 32(suppl 1):67.
144. Johnson M.D., Hamilton C.D., Drew R.H., et al. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother 2003, 51:453.
145. Van de Velde V.J.S., Van Peer A., Heykants J.J.P., et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-β-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996, 16:424.
146. Barone J.A., Moskovitz B.L., Guarnieri J., et al. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998, 18:295.
147. Barone J.A., Moskovitz B.L., Guarnieri J., et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998, 42:1862.
148. Poirier J.M., Cheymol G. Optimization of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998, 35:461.
149. Isoherranen N., Kunze K.L., Allen K.E., et al. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Disp 2004, 32:1121.
150. Pearson M.M., Rogers P.D., Cleary J.D., Chapman S.W. Voriconazole: a new triazole antifungal. Ann Pharmacother 2003, 37:420.
151. Schwartz S., Milatovic D., Eckhard T. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia. Br J Haematol 1997, 97:663.
152. Johnson L.B., Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003, 36:630.
153. Hyland R., Jones B.C., Smith D.A. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Disp 2003, 31:540.
154. Walsh T.J., Karlsson M.O., Driscoll T., et al. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration. Antimicrob Agents Chemother 2004, 48:2166-2172.
155. Courtney R., Wexler D., Radwanski E., et al. Effect of food on the relative bioavailability of 2 oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004, 57:218.
156. Courtney R., Pai S., Laughlin M., et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003, 47:2788.
157. Ezzet F., Wexler D., Courtney R., et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005, 44:211.
158. Krieter P., Flannery B., Musick T., et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004, 48:3543.
159. Ullmann A.J., Cornely O.A., Burchardt A., et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or with refractory invasive fungal infection. Antimicrob Agents Chemother 2006, 50:658.
160. Gubbins P.O., Krishna G., Sansone-Parsons A., et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006, 50:1993.
161. Ghosal A., Hapngama N., Yuan Y., et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (noxafil). Drug Metab Disp 2004, 32:267.
162. Como J.A., Dismukes W.E. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994, 330:263.
163. Boucher H.W., Groll A.H., Chiou C.C., Walsh T.J. Newer systemic antifungal agents. Drugs 2004, 64:1997.
164. Pappas P.G., Kauffman C.A., Perfect J., et al. Alopecia associated with fluconazole therapy. Ann Intern Med 1995, 123:354.
165. Terrell C.L. Antifungal agents. Part II. The azoles. Mayo Clin Proc 1999, 74:78.
166. Willems L., van der Geest R., de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001, 26:159.
167. Tan K., Brayshaw N., Tomaszewski K., et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse effects or liver function test abnormalities. J Clin Pharmacol 2006, 46:235.
168. Lazarus H.M., Blumer J.L., Yanovich S., et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002, 42:395-402.
169. Purkins L., Wood N., Ghahramani P., et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002, 46:2546.
170. Denning D.W., Ribaud P., Milpied N., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563.
171. Lutsar I., Hodges M.R., Tomaszewski K., et al. Safety of voriconazole and dose individualization. Clin Infect Dis 2003, 36:1087.
172. Hector R.F. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993, 6:1.
173. Kurtz M.B., Heath I.B., Marrinan J., et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994, 38:1480.
174. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003, 47:3149.
175. Pfaller M.A., Boyken L., Hollis R.J., et al. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005, 43:5425.
176. Pfaller M.A., Diekema D.J., Messer S.A., et al. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003, 47:1068.
177. Cuenca-Estrella M, Rodriguez D, Almirante B, et al, for the Barcelona Candidemia Project Study Group. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 55:194, 2005.
178. Oakley K.L., Moore C.B., Denning D.W. In vitro activity of the echinocandin antifungal agent LY303,366 and comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 1998, 42:2726.
179. Bowman J.C., Hicks P.S., Kurtz M.B., et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002, 46:3001.
180. Kurtz M.B., Heath I.B., Marrinan J., et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994, 38:1480.
181. Chiou C.C., Mavrogiorgos N., Tillem E., et al. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 2001, 45:3310.
182. Denning D.W. Echinocandin antifungal drugs. Lancet 2003, 362:1142.
183. Stone J.A., Xu X., Winchell G.A., et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004, 48:815.
184. Sandhu P., Lee W., Xu X., et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Disp 2005, 33:676.
185. Balani S.K., Xu X., Arison B.H., et al. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Disp 2000, 28:1274.
186. Hebert M.F., Smith H.E., Marbury T.C., et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005, 45:1145.
187. Cappelletty D., Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007, 27:369.
188. Joseph J.M., Jain R., Danziger L.H. Micafungin: a new echinocandin antifungal. Pharmacotherapy 2007, 27:53.
189. Stogniew M., Pu F., Henkel T., Dowell J. Anidulafungin biotransformation in humans is by degradation not metabolism. Clin Microbiol Infect 2003, 9(suppl):291.
190. Darkes M.J.M., Scott L.J., Goa K.L. Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol 2003, 4:39.
191. Jensen J.C. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 1989, 14:110.
192. Kovarik J.M., Kirkesseli S., Humbert H., et al. Dose-pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol 1992, 126:8.
193. Vickers A.E., Sinclair J.R., Zollinger M., et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Disp 1999, 27:1029.
194. Ryder N.S., Frank I. Interaction of terbinafine with human serum and proteins. J Med Vet Mycol 1992, 30:451.
195. Gubbins P.O., Amsden J.R. Drug-drug interactions of antifungal agents and implications for patient care. Exp Opin Pharmacother 2005, 6:2231.
196. Templeton I.E., Thummel K.E., Kharasch E.D., et al. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2008, 83(1):77.
197. Black D.J., Kunze K.L., Wienkers L.C., Warfarin-fluconazole R.B.R. a metabolically based drug interaction: in vivo studies. Drug Metab Disp 1996, 24:422.
198. Muijser R.B.R., Goa K.L., Scott L.J. Voriconazole in the treatment of invasive aspergillosis. Drugs 2002, 18:2655.
199. Wexler D., Courtney R., Richards W., et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004, 21:645.
200. Lin J.H., Yamazaki M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 2003, 35:417.
201. Gubbins P.O. Drug-drug interactions of antifungal agents and implications for patient care. J Invasive Fungal Infect 2007, 1:144.
202. Wacher V.J., Wu C.J., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 1995, 13:129.
203. Eytan G.D., Regev R., Oren G., Assaraf Y.G. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem 1996, 271:12897.
204. Ferte J. Analysis of tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem 2000, 267:277.
205. Wang E.J., Lew K., Casciano C.N., et al. Interaction of common azole antifungals with P-glycoprotein. Antimicrob Agents Chemother 2002, 46:160.
206. Penzak S.R. Mechanisms of drug interactions II: Transport proteins. Drug Interactions in Infectious Diseases 2005, 41-82. Humana Press, Totowa, NJ. S.C. Piscitelli, K. Rodvold (Eds.).
207. Gubbins P.O. Mould active azoles: pharmacokinetics, drug interactions in neutropenic hosts. Curr Opin Infect Dis 2007, 20(6):579.
208. Krishna G., Parsons A., Kantesaria B., Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007, 23:545.
209. Sasone-Parsons A., Krishna G., Martinho M., et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007, 27:825.
210. Krishna G., Sasone-Parsons A., Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin 2007, 23:1415.
211. Saad A.H., DePestel D.D., Carver P.L. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006, 26:1730.
212. Stone J.A., Migoya E.M., Hickey L., et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004, 48:4306.
213. Hebert M.F., Blough D.K., Townsend R.W., et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005, 45:1018.
214. Hebert M.F., Townsend R.W., Austin S., et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005, 45:954.
215. Dowell J.A., Stogniew M., Krause D., et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005, 45:227.
216. Dowell J.A., Stogniew M., Krause D., et al. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007, 47:305.
217. Dowell J.A., Schranz J., Baruch A., Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005, 45:1373.
218. Venkatakrishnan K., von Moltke L.L., Greenblatt D.J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000, 38:111.
219. Gubbins P.O., McConnell S.A., Amsden J.R. Drug interactions associated with antifungal agents. Drug Interactions in Infectious Diseases 2005, 289-337. Humana Press, Totowa, NJ. S.C. Piscitelli, K. Rodvold (Eds.).
220. Graybill J.R. Antifungal drugs and resistance. Adv Exp Med Biol 1995, 390:217.
221. Warnock D.W., Amphotericin B. an introduction. J Antimicrob Chemother 1991, 28(suppl B):27.
222. vanden Bossche H., Warnock D.W., DuPont B., et al. Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol 1994, 32(suppl 1):189.
223. Hamilton-Miller J.M. Polyene resistance in yeasts: a consideration of physiological and biochemical mechanisms. Microbios 1973, 8:209.
224. Nolte F.S., Parkinson T., Falconer D.J., et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997, 41:196.
225. Lupetti A., Danesi R., Campa M., et al. Molecular basis of resistance to azole antifungals. Trends Mol Med 2002, 8:76.
226. Vandeputte P., Tronchin C., Berges T., et al. Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob Agents Chemother 2007, 51:982.
227. Safe L.M., Safe S.H., Subden R.E., Morris D.C. Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis. Can J Microbiol 1977, 23:398.
228. Geraghty P., Kavanagh K. Erythromycin, an inhibitor of mitoribosomal protein biosynthesis, alters the amphotericin B susceptibility of Candida albicans. J Pharm Pharmacol 2003, 55:179.
229. Stiller R.L., Bennett J.E., Scholer H.J., et al. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother 1982, 22(3):482.
230. Weber S., Polak A. Susceptibility of yeast isolates from defined German patient groups to 5-fluorocytosine. Mycoses 1992, 35:163.
231. Redding S., Smith J., Farinacci M., et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994, 18:240.
232. He X., Tiballi R.N., Zarins L.T., et al. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994, 38:2495.
233. Thomas-Greber E., Korting H.C., Bogner J., Goebel F.D. Fluconazole-resistant oral candidosis in a repeatedly treated female AIDS patient. Mycoses 1994, 37:35.
234. Revankar S.G., Kirkpatrick W.R., McAtee R.K., et al. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996, 174:821.
235. Masia Canuto M., Gutierrez Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002, 2:550.
236. Perea S., Patterson T.F. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002, 35:1073.
237. Spanakis E.K., Aperis G., Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006, 43:1060.
238. Rex J.H., Rinaldi M.G., Pfaller M.A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995, 39:1.
239. Nguyen M.H., Peacock J.E., Morris A.J., et al. The changing face of candidemia: emergence of non- Candida albicans species and antifungal resistance. Am J Med 1996, 100:617.
240. Powderly W.G. Resistant candidiasis. AIDS Res Hum Retroviruses 1994, 10:925.
241. Hitchcock C.A. Resistance of Candida albicans to azole antifungal agents. Biochem Soc Trans 1993, 21:1039.
242. Pfaller M.A., Diekema D.J. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J Invasive Fungal Infect 2007, 1:74.
243. Xiao L., Madison V., Chau A.S., et al. Three-dimensional models of wild-type and mutated forms of cytochrome P-450 14alpha-sterol demethylases from Aspergillus fumigatis and Candida albicans provide insights into posaconazole binding. Antimicro Agents Chemother 2004, 48:568.
244. White T.C., Marr K.A., Bowden R.A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998, 11:382.
245. Sanglard D., Odds F.C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002, 2:73.
246. Li X., Brown N., Chau A.S., et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 2004, 53:74.
247. Marr K.A., Lyons C.N., Rustad T.R., et al. Rapid transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother 1998, 42:2584.
248. Sanglard D., Kuchler K., Ischer F., et al. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995, 39:2378.
249. Sanglard D., Ischer F., Monod M., Bille J. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and metabolic inhibitors. Antimicrob Agents Chemother 1996, 40:2300.
250. Sanglard D., Ischer F., Monod M., Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997, 143:405.
251. Arikan S., Paetznick V., Rex J.H. Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2002, 46:3084.
252. Pfaller M.A., Marco F., Messer S.A., Jones R.N. In vitro activity of two echinocandin derivatives, LY303366, and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998, 30:251.
253. Ha Y.S., Covert S.F., Momany M. FsFKS1, the 1,3-beta-glucan synthase from the caspofungin-resistant fungus Fusarium solani. Eukaryot Cell 2006, 5:1036.
254. Rogers T.R., Johnson E.M., Munro C. Echinocandin antifungal drug resistance. J Invasive Fungal Infect 2007, 1:99.